UTv Videos

“I think it's important as urologists to try to understand how we fit into this scheme and how we can participate in value-based care in a meaningful way without negatively affecting patients,” says Avinash Maganty, MD.

Alexandra Sokolova, MD, discusses unanswered questions and next steps with PARP inhibitors in the prostate cancer treatment paradigm.

Arya Mariam Roy, MBBS, discusses the effect of neoadjuvant chemotherapy on overall survival in patients with sarcomatoid bladder cancer.

The phase 2 CaboPoint trial is exploring cabozantinib in patients with locally advanced or metastatic renal cell carcinoma who progressed after first-line checkpoint inhibitor–based combination therapy.

“[Collagenase clostridium histolyticum (Xiaflex)] is an incredibly important part of the treatment armamentarium for Peyronie's disease in the US,” says Matthew J. Ziegelmann, MD.

"The [SWIU meeting] is a meeting that provides updates to all of our members about the exciting initiatives that the organization has been able to accomplish in the preceding year, as well as the initiatives that are planned for the subsequent year," says Akanksha Mehta, MD, MS.

“We do see that the device appears to be clinically efficacious,” says Colin Goudelocke, MD.

"I think there's going to be a rapid adoption of artificial intelligence platforms in our field," says David Sheyn, MD.

“We would like to use all of what we've learned in the MAPP to move back into the space of clinical trials and trying to identify effective therapies for this condition,” says Alisa J. Stephen-Shields, PhD.

"Where it's feasible and where the patients are eligible, I and others are trying to use alternative therapies, which have probably a similar impact in terms of improving longevity of life for patients [with prostate cancer]," says Praful Ravi, MD, BChir, MRCP.

"The first main finding was after adjusting for individual physician characteristics as well as the characteristics of the actual patient case mix for each physician, we found that small practices performed poorly compared with larger practices," says Avinash Maganty, MD.

“This is a lifetime disease; you want to make sure that the battery not just has long enough life but still has the capacity,” says Colin Goudelocke, MD.

“First, we found that we should not be using voided samples for bladder cancer research,” says Laura Bukavina, MD, MPH.

"We unfortunately did not find any difference in pain scores [after ureteroscopy] at day 1, 2, or 3. We also didn't find any difference in use of rescue medication and rescue narcotic medication," says Karen L. Stern, MD.

“I think the most notable finding is that we did see continued benefit from each injection series,” says Matthew J. Ziegelmann, MD.

The FORMULA-509 trial evaluated post-operative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone and apalutamide post-radical prostatectomy.

"In the last couple of years, there have been at least 2 sets of great tissue simulators that have come out, and I think they're really providing an opportunity for learning HoLEP," says Smita De, MD, PhD.

“People and patients are so much more informed now, and they're so engaged in their health. It's fantastic,” says Raevti Bole, MD.

“We were a bit surprised that the males with IC/BPS didn't look more like the females with regard to the magnitude of decrease in urinary symptom severity required to feel better,” says Alisa J. Stephens-Shields, PhD.

“These shortages and declines in supply have forced practitioners to readjust their diagnostic algorithms or at least question the usual practices,” says Jacob Taylor, MD, MPH.

"UH is working on starting clinics throughout rural Northeast Ohio, and we're meeting to develop a FPMRS program, both virtual and in-person, so patients can have access to this point of care," says David Sheyn, MD.

“Many were concerned that what the MIPS policy is really measuring is an ability to track and report measures as opposed to the actual provision of quality care,” says Avinash Maganty, MD.

“I am interested in looking at postpartum issues for sexual function,” says Rachel Pope, MD, MPH.

"The ultimate goal is to have as much of our time spent on actual patient care and complex decision-making [as possible]," says David Canes, MD.

"The overarching goal is to both increase the identification of patients with urinary incontinence as well as shorten the time between diagnosis and appropriate treatment," says David Sheyn, MD.

"We wanted to make sure that it was highlighted that men really need to be screened, and it should be covered by insurance," says Adam Murphy, MD, MBA, MSCI.

“I would have to say the most exciting part of the whole conference was how many medical students and trainees were there,” says Rachel Pope, MD, MPH.

“We found a significant increase in men under 30 getting vasectomies,” says Raevti Bole, MD.